NME5 (Gene)

Organism:

Homo sapiens

Synonyms:ENTREZ:8382, HGNC:7853, MIM:603575, NM23-H5, NM23H5, NME/NM23 family member 5, NME5, NM_003551, NP_003542, RSPH23, XM_005272099, XM_017009945, XM_024446227, XM_024446228, XP_005272156, XP_016865434, XP_024301995, XP_024301996

Omim:OMIM:603575

Id:ENSG00000112981

Hgnc:HGNC:7853

Entrez:8382

Ensembl:ENSG00000112981

Description:NME/NM23 family member 5

Predicted to enable nucleoside diphosphate kinase activity. Predicted to be involved in negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway and spermatid development. Predicted to act upstream of or within cilium assembly; epithelial cilium movement involved in extracellular fluid movement; and ventricular system development. Predicted to be located in cilium. [provided by Alliance of Genome Resources, Apr 2022]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View NME5's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with NME5.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using NME5.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for NME5.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with NME5.

Results found

Linked to

	Label	Description
	GSE114492 GSE153671 KMT2D inhibition 6 v 8 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE144443 0 V 6 NICOTINAMIDE MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE216043 cisplatin 11 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE228106 3 V 5 PACLITAXEL HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE114492 GSE153671 KMT2D inhibition 10 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE143782 calcitriol 7 v 11 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE158431 2 V 0 PIOGLITAZONE MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE81796 0 V 2 ENZALUTAMIDE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE210655 1 V 0 CISPLATIN MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE202434 GSE202438 talazoparib 3 v 11 human dn Gene Set (Entity type)	A Gene Set from LINCS

GSE114492 GSE153671 KMT2D inhibition 6 v 8 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE144443 0 V 6 NICOTINAMIDE MOUSE UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE216043 cisplatin 11 v 2 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE228106 3 V 5 PACLITAXEL HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE114492 GSE153671 KMT2D inhibition 10 v 7 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE143782 calcitriol 7 v 11 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE158431 2 V 0 PIOGLITAZONE MOUSE UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE81796 0 V 2 ENZALUTAMIDE HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE210655 1 V 0 CISPLATIN MOUSE UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE202434 GSE202438 talazoparib 3 v 11 human dn

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.